Rhythm (RYTM) | Financial Analysis & Statements
Rhythm Pharmaceuticals Inc. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
57.3M
Gross Profit
52.5M
91.61%
Operating Income
-47.1M
-82.20%
Net Income
-47.5M
-82.97%
Balance Sheet Metrics
Total Assets
480.2M
Total Liabilities
210.2M
Shareholders Equity
270.0M
Debt to Equity
0.78
Cash Flow Metrics
Operating Cash Flow
-21.1M
Free Cash Flow
-26.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Rhythm Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 189.8M | 130.1M | 77.4M | 23.6M | 3.2M |
| Cost of Goods Sold | 19.5M | 13.4M | 9.3M | 2.1M | 599.0K |
| Gross Profit | 170.3M | 116.8M | 68.1M | 21.5M | 2.6M |
| Gross Margin % | 89.7% | 89.7% | 88.0% | 91.0% | 81.0% |
| Operating Expenses | |||||
| Research & Development | 167.3M | 238.0M | 135.0M | 108.6M | 104.1M |
| Selling, General & Administrative | 194.9M | 144.3M | 117.5M | 92.0M | 68.5M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 362.3M | 382.3M | 252.5M | 200.7M | 172.6M |
| Operating Income | -192.0M | -265.5M | -184.4M | -179.2M | -170.1M |
| Operating Margin % | -101.2% | -204.0% | -238.1% | -757.9% | -5,391.9% |
| Non-Operating Items | |||||
| Interest Income | 15.3M | 14.7M | 13.9M | 4.0M | 447.0K |
| Interest Expense | 20.6M | 20.6M | 13.9M | 5.2M | 0 |
| Other Non-Operating Income | 1.3M | 11.1M | 190.0K | -790.0K | 100.0M |
| Pre-tax Income | -196.0M | -260.3M | -184.1M | -181.1M | -69.6M |
| Income Tax | 497.0K | 346.0K | 564.0K | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -196.5M | -260.6M | -184.7M | -181.1M | -69.6M |
| Net Margin % | -103.6% | -200.3% | -238.5% | -766.2% | -2,207.1% |
| Key Metrics | |||||
| EBITDA | -174.1M | -247.0M | -168.5M | -174.2M | -68.5M |
| EPS (Basic) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| EPS (Diluted) | $-3.11 | $-4.34 | $-3.20 | $-3.47 | $-1.40 |
| Basic Shares Outstanding | 64984361 | 60995204 | 57673128 | 52120701 | 49600294 |
| Diluted Shares Outstanding | 64984361 | 60995204 | 57673128 | 52120701 | 49600294 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Rhythm Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 54.3M | 89.1M | 60.1M | 127.7M | 59.2M |
| Short-term Investments | 334.6M | 231.4M | 215.8M | 205.6M | 235.6M |
| Accounts Receivable | 26.1M | 18.5M | 14.9M | 6.2M | 1.0M |
| Inventory | 25.8M | 18.7M | 8.6M | 2.9M | 111.0K |
| Other Current Assets | 10.0M | 8.8M | 6.7M | 7.4M | 4.0M |
| Total Current Assets | 466.9M | 374.2M | 308.3M | 354.2M | 308.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 3.0M | 3.5M | 781.0K | 1.2M | 1.5M |
| Goodwill | 5.3M | 6.2M | 7.0M | 7.9M | 4.7M |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 3.8M | 7.8M | 15.3M | 17.0M | 12.1M |
| Total Non-Current Assets | 13.3M | 18.1M | 24.5M | 28.2M | 21.1M |
| Total Assets | 480.2M | 392.3M | 332.7M | 382.5M | 329.5M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 13.9M | 12.3M | 4.9M | 4.8M | 5.7M |
| Short-term Debt | 650.0K | - | 770.0K | 684.0K | 606.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 4.1M | 42.1M | 5.4M | 2.4M | 800.0K |
| Total Current Liabilities | 105.9M | 115.5M | 55.2M | 39.8M | 43.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 3.3M | 3.9M | 490.0K | 1.3M | 1.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 104.2M | 112.2M | 107.8M | 78.4M | 1.9M |
| Total Liabilities | 210.2M | 227.7M | 163.0M | 118.2M | 45.4M |
| Equity | |||||
| Common Stock | 67.0K | 61.0K | 59.0K | 56.0K | 50.0K |
| Retained Earnings | -1.4B | -1.2B | -894.7M | -710.1M | -528.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 270.0M | 164.5M | 169.8M | 264.3M | 284.2M |
| Key Metrics | |||||
| Total Debt | 4.0M | 3.9M | 1.3M | 1.9M | 2.6M |
| Working Capital | 361.0M | 258.7M | 253.1M | 314.4M | 265.0M |
Balance Sheet Composition
Rhythm Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -196.5M | -260.6M | -184.7M | -181.1M | -69.6M |
| Depreciation & Amortization | 1.3M | 1.6M | 1.8M | 1.7M | 1.2M |
| Stock-Based Compensation | 66.8M | 39.7M | 32.6M | 19.8M | 20.8M |
| Working Capital Changes | 5.4M | 16.1M | 1.9M | -17.9M | 5.2M |
| Operating Cash Flow | -101.9M | -89.9M | -129.0M | -172.4M | -42.7M |
| Investing Activities | |||||
| Capital Expenditures | -953.0K | 0 | -47.0K | -281.0K | -434.0K |
| Acquisitions | - | - | 0 | 0 | 100.0M |
| Investment Purchases | -348.7M | -268.3M | -354.9M | -251.9M | -525.0M |
| Investment Sales | 252.5M | 260.6M | 355.0M | 284.2M | 361.2M |
| Investing Cash Flow | -137.2M | -48.2M | -5.7M | 32.0M | -64.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 202.8M | 174.0M | 65.8M | 203.4M | 161.7M |
| Free Cash Flow | -116.6M | -113.9M | -136.2M | -177.7M | -151.4M |
| Net Change in Cash | -36.3M | 36.0M | -68.8M | 63.1M | 54.9M |
Cash Flow Trend
Rhythm Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-27.39
Forward P/E
-217.51
Price to Book
41.04
Price to Sales
30.56
PEG Ratio
-19.72
Profitability Ratios
Profit Margin
-103.57%
Operating Margin
-82.20%
Return on Equity
-90.45%
Return on Assets
-27.51%
Financial Health
Current Ratio
4.41
Debt to Equity
41.54
Beta
2.14
Per Share Data
EPS (TTM)
$-3.11
Book Value per Share
$2.07
Revenue per Share
$2.92
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| RYTM | 5.8B | -27.39 | 41.04 | -90.45% | -103.57% | 41.54 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Axsome Therapeutics | 9.5B | -50.54 | 105.31 | -252.12% | -28.69% | 247.03 |
| Praxis Precision | 9.6B | - | 9.46 | -45.83% | 0.00% | 0.01 |
| Bio-Techne | 9.1B | 117.16 | 4.55 | 3.80% | 6.41% | 20.07 |
Financial data is updated regularly. All figures are in the company's reporting currency.






